The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
CREATE Bio Optimization Track for Biologics (SBIR-U44)
This Funding Opportunity Announcement (FOA) supports SBIRs in the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging modalities) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic agent(s) that showed promise as evidenced by relevant, rigorous, convincing in vivo studies. Therefore, at the end of this funding period, successful projects will have delivered an optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track.
Companion FOA: PAR-17-456, U01 Research Project – Cooperative Agreement
- Application Due Date(s): February 13, 2018; July 18, 2018; February 13, 2019; July 18, 2019; February 13, 2020; and July 20, 2020
- AIDS Application Due Date(s): May 7, 2018; September 7, 2018; May 7, 2019; September 7, 2019; May 7, 2020; and September 7, 2020
PAR-17-457 Expiration Date September 8, 2020
Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.
Application budgets are not limited but must reflect the actual needs of the proposed project. Budgets for these projects will normally remain under $700,000 total cost (direct costs, indirect costs, fee) per year in Phase I and $4,000,000 total cost for Phase II (no more than $1,500,000 in total costs per year in Phase II). Budget costs will likely fluctuate over the funding period based on the stage of the project.